Sai Life Sciences to Recruit 700+ Professionals in FY27

The recruitment drive aims to attract high-caliber scientists to support growing demand for end-to-end drug discovery, development, and manufacturing services.

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Sai Life Sciences Limited, an Indian contract research, development, and manufacturing organization (CRDMO), announced plans to hire over 700 scientific, technical, and management professionals during the 2026-27 fiscal year. The recruitment drive will span roles across various functions including medicinal chemistry, biology, DMPK, process and analytical development, formulation development, and more. The company aims to attract high-caliber scientists from leading institutions globally to support the increasing complexity of programs and higher scientific expectations from global innovator companies.

Why it matters

The planned expansion reflects the growing demand for high-quality, integrated CRDMO partners in India as global supply chains are rebalanced and the need for resilient development and manufacturing partners increases. It also highlights the rising sophistication of outsourced science, creating exciting opportunities for Indian scientists to work on globally relevant, high-impact programs without compromising on scientific rigor or exposure.

The details

Sai Life Sciences operates across India, the UK, and the US, serving global pharmaceutical and biotechnology companies. The majority of the new roles will be based in Hyderabad, home to the company's largest integrated R&D campus. The recruitment drive will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up. As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth.

  • Sai Life Sciences announced the hiring plans for the 2026-27 fiscal year.

The players

Sai Life Sciences Limited

An Indian contract research, development, and manufacturing organization (CRDMO) that provides end-to-end drug discovery, development, and manufacturing services to global pharmaceutical and biotechnology companies.

Krishna Kanumuri

The CEO and Managing Director of Sai Life Sciences.

Got photos? Submit your photos here. ›

What they’re saying

“We are at an inflection point for the Indian CRDMO industry. Global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India's favour. Demand for high-quality, integrated partners is already visible, and this expansion is about preparing ourselves to serve that demand at scale — with the right infrastructure, strong digital and quality systems, and deep scientific capability.”

— Krishna Kanumuri, CEO & Managing Director (BusinessWire)

“For scientists, this is a genuinely exciting moment. They have the opportunity to work on globally relevant, high-impact programs while being based in India. We believe this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers here—without compromising on scientific rigor, exposure, or the quality of work.”

— Krishna Kanumuri, CEO & Managing Director (BusinessWire)

The takeaway

Sai Life Sciences' planned expansion reflects the growing demand for high-quality CRDMO partners in India, driven by global supply chain shifts and the increasing sophistication of outsourced drug discovery and development work. This presents an exciting opportunity for Indian scientists to contribute to globally relevant, high-impact programs while being based in India.